Tuesday, May 23, 2017

Galectin Therapeutics: Serendipity In Psoriasis, Strength In Nash.


  • Building presence in the NASH market with lead molecule GR-MD-02 while developing its applications for other conditions
  • Serendipitous finding for plaque psoriasis suggests positive outcome for both plaque psoriasis and NASH in future trials
  • Expert management and adequate capital provide the all-important margin of safety for prudent investment
  • Highly asymmetric investing risks to rewards for the intelligent biotech investors


Galectin Therapeutics (NASDAQ:GALT) is a small biotechnology company based in Norcross, Georgia, focusing on the innovation of medicines that inhibit galectin molecules for the treatment of various diseases such as nonalcoholic steatohepatitis (“NASH”), skin cancer and plaque psoriasis. After a temporary nosedive in 2016, share price appreciated by approximately 80% for the past 52-weeks. It is highly likely that recent capital appreciation is reflective of the firm’s increasing intrinsic value due to key developments. A notable catalyst was the positive data for the exploratory phase 2a trial, which suggests that lead molecule GR-MD-02 could be used to treat plaque psoriasis. Despite the firm’s emphasis on NASH, this research shall focus on the potential therapeutic application of GR-MD-02 for plaque psoriasis.

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research and simply want regular updates, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.